Is TVGN or MOLN more profitable?

Tevogen Bio's return on equity of 0.00% beat Molecular Partners' return on equity. Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -468.32% Molecular Partners N/A -68.36% -54.82%

Which has stronger earnings and valuation, NGEN or TVGN?

NervGen Pharma is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NervGen Pharma N/A N/A -$31.58M -$0.46 N/A Tevogen Bio N/A N/A -$26.27M -$4.63 N/A

Is NGEN or TVGN more profitable?

Tevogen Bio's return on equity of 0.00% beat NervGen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets NervGen Pharma N/A -1,259.82% -199.79% Tevogen Bio N/A N/A -468.32%

Is TVGN or SPRB more profitable?

Tevogen Bio's return on equity of 0.00% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -468.32% Spruce Biosciences N/A -123.53% -90.35%

Is HUMA or TVGN more profitable?

Tevogen Bio has a net margin of 0.00% compared to Humacyte's net margin of -4,556.29%. Tevogen Bio's return on equity of 0.00% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets Humacyte -4,556.29% -983.32% -88.84% Tevogen Bio N/A N/A -468.32%

Tevogen Bio (TVGN) Competitors

$7.34 +0.01 (+0.14%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$7.28 -0.06 (-0.82%)

As of 09/9/2026 07:30 PM Eastern

Compare

TVGN vs. MOLN, NGEN, SPRB, HUMA, and CRBU

Should you buy Tevogen Bio stock or one of its competitors? Tevogen Bio's main competitors and comparable companies include Molecular Partners (MOLN), NervGen Pharma (NGEN), Spruce Biosciences (SPRB), Humacyte (HUMA), and Caribou Biosciences (CRBU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tevogen Bio compare to Molecular Partners?

Tevogen Bio (NASDAQ:TVGN) and Molecular Partners (NASDAQ:MOLN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

26.6% of Molecular Partners shares are held by institutional investors. 65.6% of Tevogen Bio shares are held by company insiders. Comparatively, 5.9% of Molecular Partners shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Tevogen Bio's average media sentiment score of 0.00 equaled Molecular Partners'average media sentiment score.

Company	Overall Sentiment
Tevogen Bio	Neutral
Molecular Partners	Neutral

Tevogen Bio has higher earnings, but lower revenue than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A
Molecular Partners	$5.65M	30.62	-$74.41M	-$1.71	N/A

Tevogen Bio presently has a consensus target price of $100.00, suggesting a potential upside of 1,262.40%. Molecular Partners has a consensus target price of $8.38, suggesting a potential upside of 95.45%. Given Tevogen Bio's higher probable upside, research analysts clearly believe Tevogen Bio is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Tevogen Bio's return on equity of 0.00% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-468.32%
Molecular Partners	N/A	-68.36%	-54.82%

Tevogen Bio has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

Summary

Molecular Partners beats Tevogen Bio on 7 of the 12 factors compared between the two stocks.

How does Tevogen Bio compare to NervGen Pharma?

NervGen Pharma (NASDAQ:NGEN) and Tevogen Bio (NASDAQ:TVGN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

In the previous week, NervGen Pharma had 1 more articles in the media than Tevogen Bio. MarketBeat recorded 1 mentions for NervGen Pharma and 0 mentions for Tevogen Bio. NervGen Pharma's average media sentiment score of 0.00 equaled Tevogen Bio'saverage media sentiment score.

Company	Overall Sentiment
NervGen Pharma	Neutral
Tevogen Bio	Neutral

NervGen Pharma is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	-$31.58M	-$0.46	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A

Tevogen Bio's return on equity of 0.00% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	-1,259.82%	-199.79%
Tevogen Bio	N/A	N/A	-468.32%

NervGen Pharma presently has a consensus target price of $14.00, suggesting a potential upside of 557.28%. Tevogen Bio has a consensus target price of $100.00, suggesting a potential upside of 1,262.40%. Given Tevogen Bio's higher probable upside, analysts plainly believe Tevogen Bio is more favorable than NervGen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

NervGen Pharma beats Tevogen Bio on 6 of the 10 factors compared between the two stocks.

How does Tevogen Bio compare to Spruce Biosciences?

Tevogen Bio (NASDAQ:TVGN) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Tevogen Bio has higher earnings, but lower revenue than Spruce Biosciences. Tevogen Bio is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A
Spruce Biosciences	$4.91M	32.58	-$38.97M	-$39.78	N/A

Tevogen Bio's return on equity of 0.00% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-468.32%
Spruce Biosciences	N/A	-123.53%	-90.35%

Tevogen Bio currently has a consensus target price of $100.00, suggesting a potential upside of 1,262.40%. Spruce Biosciences has a consensus target price of $159.50, suggesting a potential upside of 186.15%. Given Tevogen Bio's higher possible upside, equities research analysts clearly believe Tevogen Bio is more favorable than Spruce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

91.7% of Spruce Biosciences shares are held by institutional investors. 65.6% of Tevogen Bio shares are held by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Spruce Biosciences had 1 more articles in the media than Tevogen Bio. MarketBeat recorded 1 mentions for Spruce Biosciences and 0 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 0.00 equaled Spruce Biosciences'average media sentiment score.

Company	Overall Sentiment
Tevogen Bio	Neutral
Spruce Biosciences	Neutral

Tevogen Bio has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.31, indicating that its stock price is 231% more volatile than the broader market.

Summary

Spruce Biosciences beats Tevogen Bio on 8 of the 13 factors compared between the two stocks.

How does Tevogen Bio compare to Humacyte?

Humacyte (NASDAQ:HUMA) and Tevogen Bio (NASDAQ:TVGN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

44.7% of Humacyte shares are owned by institutional investors. 3.1% of Humacyte shares are owned by insiders. Comparatively, 65.6% of Tevogen Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Humacyte currently has a consensus price target of $6.54, indicating a potential upside of 1,029.82%. Tevogen Bio has a consensus price target of $100.00, indicating a potential upside of 1,262.40%. Given Tevogen Bio's higher probable upside, analysts plainly believe Tevogen Bio is more favorable than Humacyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Humacyte has a beta of 2.45, indicating that its stock price is 145% more volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market.

Tevogen Bio has lower revenue, but higher earnings than Humacyte. Tevogen Bio is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	78.85	-$40.83M	-$0.49	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A

Tevogen Bio has a net margin of 0.00% compared to Humacyte's net margin of -4,556.29%. Tevogen Bio's return on equity of 0.00% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,556.29%	-983.32%	-88.84%
Tevogen Bio	N/A	N/A	-468.32%

In the previous week, Humacyte had 4 more articles in the media than Tevogen Bio. MarketBeat recorded 4 mentions for Humacyte and 0 mentions for Tevogen Bio. Humacyte's average media sentiment score of 0.75 beat Tevogen Bio's score of 0.00 indicating that Humacyte is being referred to more favorably in the media.

Company	Overall Sentiment
Humacyte	Positive
Tevogen Bio	Neutral

Summary

Humacyte beats Tevogen Bio on 10 of the 15 factors compared between the two stocks.

How does Tevogen Bio compare to Caribou Biosciences?

Tevogen Bio (NASDAQ:TVGN) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Tevogen Bio presently has a consensus target price of $100.00, indicating a potential upside of 1,262.40%. Caribou Biosciences has a consensus target price of $7.75, indicating a potential upside of 438.19%. Given Tevogen Bio's higher possible upside, equities research analysts plainly believe Tevogen Bio is more favorable than Caribou Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Caribou Biosciences had 1 more articles in the media than Tevogen Bio. MarketBeat recorded 1 mentions for Caribou Biosciences and 0 mentions for Tevogen Bio. Caribou Biosciences' average media sentiment score of 1.73 beat Tevogen Bio's score of 0.00 indicating that Caribou Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Tevogen Bio	Neutral
Caribou Biosciences	Very Positive

77.5% of Caribou Biosciences shares are owned by institutional investors. 65.6% of Tevogen Bio shares are owned by insiders. Comparatively, 8.5% of Caribou Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Tevogen Bio has higher earnings, but lower revenue than Caribou Biosciences. Tevogen Bio is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A
Caribou Biosciences	$11.16M	13.83	-$148.12M	-$1.08	N/A

Tevogen Bio has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.28, meaning that its stock price is 128% more volatile than the broader market.

Tevogen Bio has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,030.42%. Tevogen Bio's return on equity of 0.00% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-468.32%
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%

Summary

Caribou Biosciences beats Tevogen Bio on 11 of the 16 factors compared between the two stocks.

Get Tevogen Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TVGN vs. The Competition

Export

Metric	Tevogen Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$47.73M	$3.90B	$7.22B	$12.88B
Dividend Yield	N/A	3.61%	2.55%	9.95%
P/E Ratio	-1.59	12.94	271.79	25.29
Price / Sales	N/A	1,459.53	709.72	113.02
Price / Cash	N/A	107.40	77.55	52.32
Price / Book	-0.03	15.81	10.63	6.26
Net Income	-$26.27M	-$22.81M	$3.48B	$357.86M
7 Day Performance	2.37%	-0.13%	-1.19%	-0.56%
1 Month Performance	14.87%	4.54%	1.99%	-1.04%
1 Year Performance	-83.17%	46.20%	21.89%	11.31%

Tevogen Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TVGN Tevogen Bio	1.6536 of 5 stars	$7.34 +0.1%	$100.00 +1,262.4%	-83.4%	$47.73M	N/A	N/A	3
MOLN Molecular Partners	2.8405 of 5 stars	$4.23 -6.0%	$8.38 +98.0%	+13.5%	$181.69M	$5.65M	N/A	180	Positive News Gap Down
NGEN NervGen Pharma	1.5083 of 5 stars	$2.32 +5.0%	$14.00 +503.4%	N/A	$178.19M	N/A	N/A	N/A
SPRB Spruce Biosciences	2.2398 of 5 stars	$55.60 -5.7%	$159.50 +186.9%	+519.3%	$169.48M	N/A	N/A	20
HUMA Humacyte	2.4897 of 5 stars	$0.57 -5.2%	$6.54 +1,046.9%	-61.4%	$167.07M	$2.04M	N/A	150

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TVGN) was last updated on 9/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tevogen Bio (TVGN) Competitors

TVGN vs. MOLN, NGEN, SPRB, HUMA, and CRBU

How does Tevogen Bio compare to Molecular Partners?

Summary

How does Tevogen Bio compare to NervGen Pharma?

Summary

How does Tevogen Bio compare to Spruce Biosciences?

Summary

How does Tevogen Bio compare to Humacyte?

Summary

How does Tevogen Bio compare to Caribou Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN vs. The Competition

Tevogen Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tevogen Bio (TVGN) Competitors

TVGN vs. MOLN, NGEN, SPRB, HUMA, and CRBU

How does Tevogen Bio compare to Molecular Partners?

Do institutionals and insiders believe in TVGN or MOLN?

Does the media refer more to TVGN or MOLN?

Which has preferable earnings and valuation, TVGN or MOLN?

Do analysts rate TVGN or MOLN?

Is TVGN or MOLN more profitable?

Which has more volatility and risk, TVGN or MOLN?

Summary

How does Tevogen Bio compare to NervGen Pharma?

Does the media refer more to NGEN or TVGN?

Which has stronger earnings and valuation, NGEN or TVGN?

Is NGEN or TVGN more profitable?

Do analysts prefer NGEN or TVGN?

Summary

How does Tevogen Bio compare to Spruce Biosciences?

Which has stronger valuation & earnings, TVGN or SPRB?

Is TVGN or SPRB more profitable?

Do analysts rate TVGN or SPRB?

Do institutionals and insiders believe in TVGN or SPRB?

Does the media prefer TVGN or SPRB?

Which has more risk & volatility, TVGN or SPRB?

Summary

How does Tevogen Bio compare to Humacyte?

Do insiders and institutionals believe in HUMA or TVGN?

Do analysts recommend HUMA or TVGN?

Which has more risk & volatility, HUMA or TVGN?

Which has higher earnings & valuation, HUMA or TVGN?

Is HUMA or TVGN more profitable?

Does the media favor HUMA or TVGN?

Summary

How does Tevogen Bio compare to Caribou Biosciences?

Do analysts rate TVGN or CRBU?

Does the media refer more to TVGN or CRBU?

Do insiders & institutionals believe in TVGN or CRBU?

Which has stronger earnings & valuation, TVGN or CRBU?

Which has more volatility and risk, TVGN or CRBU?

Is TVGN or CRBU more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN vs. The Competition

Tevogen Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools